TPWA
PRME icon

Twin Peaks Wealth Advisors’s Prime Medicine PRME Stock Holding History

Twin Peaks Wealth Advisors’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10 Buy
+3
New +$11 ﹤0.01% 2365

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Twin Peaks Wealth Advisors's PRME Position: Q1 2026 in Review

Twin Peaks Wealth Advisors opened a new position in Prime Medicine (PRME) in Q1 2026: 3 shares worth $10. The stake represents ﹤0.01% of the portfolio and ranks #2365 among its holdings.

192 funds tracked by Wall St. Rank hold PRME as of Q1 2026.

  • Twin Peaks Wealth Advisors held 3 shares of Prime Medicine worth $10 as of Q1 2026.
  • Prime Medicine was a new Twin Peaks Wealth Advisors position in Q1 2026.
  • Prime Medicine made up ﹤0.01% of Twin Peaks Wealth Advisors's portfolio in Q1 2026, its #2365 holding.
  • 192 funds tracked by Wall St. Rank held Prime Medicine as of Q1 2026.

Based on Twin Peaks Wealth Advisors's 13F filing for Q1 2026, filed 8 May 2026.